JPMorgan initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $23 price target The firm says its ...

CAMP4 Therapeutics raises $75 million in IPO, advances RNA therapies for rare diseases, and partners with BioMarin. Analysts ...

Fintel reports that on November 5, 2024, Leerink Partners initiated coverage of Camp4 Therapeutics (NasdaqGM:CAMP) with a ...

Camp4 Therapeutics CEO Josh Mandel-Brehm said the biotech's IPO shows a changing environment. After Camp4 Therapeutics Inc. made its Nasdaq debut on Friday, founding CEO Josh Mandel-Brehm said the ...

Recently IPO'ed biotech Camp4 Therapeutics (NASDAQ:CAMP) recorded its best intraday gains since its public debut in October as J.P. Morgan and Piper Sandler launched its coverage with Overweight ...

CAMP4 is focused on addressing the fundamental cause of disease by controlling the output of genes central to disease. By taking advantage of the gene circuitry code, CAMP4 is able to control gene ...

Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead ...

CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA ...

Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings. Individual or Entity Most Recent Transaction Date Shares Owned as of Transaction Date 5AM PARTNERS VI ...

JPMorgan initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $23 price target The firm says its bullish thesis is based on Camp4’s ASO RNA Actuator Platform ...

Leerink initiated coverage of Camp4 Therapeutics (CAMP) with an Outperform rating and $17 price target The firm believes CMP-CPS-001, the lead program in urea cycle disorders, offers a pathway to ...